Genmab AS (GMAB)vsRoyalty Pharma Plc (RPRX)
GMAB
Genmab AS
$25.15
+1.70%
HEALTHCARE · Cap: $15.40B
RPRX
Royalty Pharma Plc
$55.02
-1.09%
HEALTHCARE · Cap: $31.60B
Smart Verdict
WallStSmart Research — data-driven comparison
Genmab AS generates 60% more annual revenue ($3.90B vs $2.44B). RPRX leads profitability with a 33.9% profit margin vs 21.0%. GMAB appears more attractively valued with a PEG of 1.67. RPRX earns a higher WallStSmart Score of 65/100 (C+).
GMAB
Buy62
out of 100
Grade: C+
RPRX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+46.6%
Fair Value
$56.30
Current Price
$25.15
$31.15 discount
Margin of Safety
-59.6%
Fair Value
$34.38
Current Price
$55.02
$20.64 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 21 of every $100 in revenue as profit
Reasonable price relative to book value
Strong operational efficiency at 25.1%
Revenue surging 25.3% year-over-year
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Areas to Watch
Expensive relative to growth rate
Distress zone — elevated risk
Weak financial health signals
Earnings declined 72.8%
Expensive relative to growth rate
Moderate valuation
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : GMAB
The strongest argument for GMAB centers on Profit Margin, Price/Book, Operating Margin. Profitability is solid with margins at 21.0% and operating margin at 25.1%. Revenue growth of 25.3% demonstrates continued momentum.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : GMAB
The primary concerns for GMAB are PEG Ratio, Altman Z-Score, Piotroski F-Score.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
GMAB profiles as a growth stock while RPRX is a mature play — different risk/reward profiles.
GMAB carries more volatility with a beta of 0.68 — expect wider price swings.
GMAB is growing revenue faster at 25.3% — sustainability is the question.
RPRX generates stronger free cash flow (761M), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (65/100 vs 62/100), backed by strong 33.9% margins and 11.0% revenue growth. GMAB offers better value entry with a 46.6% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Genmab AS
HEALTHCARE · BIOTECHNOLOGY · USA
Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
Visit Website →Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?